The pharmaceutical company's shares have seen an increase of 1.87% over the last month, surpassing the Medical sector's gain of 0.71% and falling behind the S&P 500's gain of 3.82%. Investors should also note any recent changes to analyst estimates for Organon. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. The Zacks Rank system, running from #1 (Strong Buy) to #5 (St ...